China Resources Boya Bio-pharmaceutical Group (300294.SZ) announced a forecasted increase, with expected net profit for the year expected to be between 380 million and 480 million yuan, a year-on-year growth of 60.03% to 102.14%.

China Resources Boya Bio-pharmaceutical Group (300294.SZ) disclosed its performance forecast for 2024, with the company expecting a net profit attributable to shareholders of the listed company of 3.8 billion to 4.8 billion yuan, a year-on-year increase of 60.03% to 102.14%; the net profit after deducting non-recurring gains and losses is expected to be 2.84 billion to 3.84 billion yuan, a year-on-year increase of 98.32% to 168.22%.